Ligand pharmaceuticals inc
LGND 投資分析
看多重點：
- 價值≥4
- 股利≥2
價值 3 分
基本面表現一般，但獲利仍相對平穩，屬於較穩健的公司
股利 1 分
沒有發放股利紀錄
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
LGND 近期報酬表現
-1.80%
Ligand pharmaceuticals inc
-0.72%
同產業平均
-0.20%
S&P500
與 LGND 同產業的標的表現
| 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 市值 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VCYT Veracyte inc | 3 分 | 4 分 | 2 分 | 3 分 | 1 分 | 1.9B | |
MDXH Mdxhealth sa - adr | - | 3 分 | 2 分 | 1 分 | 1 分 | 89M | |
DTIL Precision biosciences inc | 4 分 | 2 分 | 2 分 | 1 分 | 1 分 | 49.2M | |
TGTX Tg therapeutics inc | 3 分 | 4 分 | 4 分 | 3 分 | 1 分 | 1.9B | |
NVTA Invitae corp | 2 分 | 1 分 | 2 分 | 2 分 | 1 分 | 154.8M |
- VCYT Veracyte inc價值 3 分趨勢 4 分波段 2 分籌碼 3 分股利 1 分市值 1.9B查看更多
LGND 公司資訊
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. Its products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and others. Kyprolis is formulated with its Captisol technology. Teriparatide Injection is a drug indicated for use including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. It also owns berdazimer gel and all the assets related to the NITRICIL technology platform, and rights to Sitavig program.